CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 15, 2018--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that its President and Chief Executive Officer, John P. Butler, will present at the UBS Global Healthcare Conference on Tuesday, May 22, 2018, at 4:00 p.m. Eastern Time, at the Grand Hyatt New York in New York City.

A live webcast of the presentation will be available on the company’s website at www.akebia.com. To access the webcast, please log onto the Akebia website at least 15 minutes prior to the webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Akebia’s website following the conference.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at  www.akebia.com, which does not form a part of this release.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180515005100/en/

CONTACT: Akebia Therapeutics

John Garabo, 617-844-6130

Director, Corporate Communications

jgarabo@akebia.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Akebia Therapeutics, Inc.

Copyright Business Wire 2018.

PUB: 05/15/2018 04:05 PM/DISC: 05/15/2018 04:05 PM

http://www.businesswire.com/news/home/20180515005100/en